Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...

The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association ...

Zongertinib, as defined by the National Cancer Institute on its website, is an oral inhibitor of HER2 which prevents HER2-mediated signaling and may lead to cell death in HER2-expressing tumor cells.

Tyrosine kinase inhibitors (TKIs) have become increasingly important in the treatment of multiple cancers. They basically work by blocking signaling pathways that drive tumor growth in cancer.

The panel of experts provide their closing thoughts on the burden of disease in leukemia and lymphoma and the Bruton tyrosine kinase inhibitor landscape. 2 Commerce Drive Suite 100 Cranbury, NJ ...

Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined w ...

FLT3 IDT confers a poor prognosis in AML patients, as it promotes leukemic cell survival and proliferation through ... transcription, and mitochondrial biogenesis in FLT3-mutant leukemia. ... J, Lu WH ...

Mantle-cell lymphoma (MCL) is an aggressive, rare subtype of B-cell non-Hodgkin lymphoma. Covalent Bruton tyrosine kinase inhibitors (cBTKi) have transformed the therapeutic landscape of multiple ...

In accordance with these new discoveries in mice, Rbm25 activity is also negatively correlated with white blood cell counts that mark poor survival in human patients with myeloid leukemia.